drugset / Trial / NCT01244490
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
RandomizedParallel-groupTriple-blindTreatment
Summary
For children and adolescents, how does SPD503 compare to placebo for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
Timeline
- Start
- 2011-01-17
- Primary completion
- 2013-05-01
- Completion
- 2013-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atomoxetine | Other / unclassified | 10 mg | — |
| Subject | Atomoxetine | Other / unclassified | 100 mg | — |
| Subject | Guanfacine | Small molecule | 0.05 mg/kg | — |
| Subject | Guanfacine | Small molecule | 0.12 mg/kg | — |
| Subject | Guanfacine | Small molecule | 1 mg | — |
| Subject | Guanfacine | Small molecule | 4 mg | — |
| Subject | Guanfacine | Small molecule | 7 mg | — |